Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 16/20 | 0.37 |
| ▸ | HRH1 | P35367 | 15/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177838 | 0.87 | HRH1 (0.36) | CCR3HRH1KCNH2FFAR4 | |
| SCHEMBL1177831 | 0.87 | HRH1 (0.41) | CCR3HRH1KCNH2 | |
| SCHEMBL1177675 | 0.87 | CCR3 (0.37) | CCR3HRH1KCNH2MEN1KMT2A | |
| SCHEMBL1177586 | 0.86 | HRH1 (0.36) | CCR3HRH1KCNH2FFAR4 | |
| SCHEMBL1177560 | 0.80 | HRH3 (0.38) | CCR3HRH1MEN1KMT2AKDM4E | |
| SCHEMBL1177492 | 0.79 | CHRNA3 (0.36) | CCR3HRH1KCNH2FFAR4 | |
| SCHEMBL1177547 | 0.77 | EPHX2 (0.36) | CCR3HRH1KCNH2 | |
| SCHEMBL1177812 | 0.77 | PGR (0.43) | — | |
| SCHEMBL1178276 | 0.76 | KDM2B (0.38) | KCNH2 | |
| SCHEMBL1178133 | 0.75 | EPHX2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | PETERS DAN | 2011-05-12 | — | — | US | disclosed |
| US-7888358-B2 | Serotonine, dopamine and norendrenaline receptors; antidepressants, anxiolytic agents, eating disorders; obesity; bipolar; drug abuse; neurodegenerative diseases | NEUROSEARCH A/S (DK) | 2011-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112139-A1 | NOVEL 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | CCR3 2996/4885HRH1 770/4885KCNH2 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.